KLF5 and breast cancer: Studies have reported that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) inhibited the protein expression of KLF5 in breast cancer by increasing KLF5 protein lysine 369 (K369) acetylation levels.[35] Therefore, we explored the regulatory role of SAHA in KLF5 expression in OC cells.